{"doi":"10.1002/hon.3165_564","title":"DIFFUSE LARGE B‐CELL LYMPHOMA: REAL‐WORLD CLINICAL EXPERIENCE WITH RITUXIMAB PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE IN CUBA","abstract":"Non-Hodgkin’s lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders. Diffuse large B-Cell Lymphoma (DLBCL) is the most common NHL in adults, it accounts around 30-40% of all NHL. Chemoimmunotherapy regimen based on Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is the standard of care for DLBCL patients. The present study investigated its application in the real-world clinical practice at a single institution in Cuba. Data of patients diagnosed from DLBCL and treated with R-CHOP from January 2008 to June 2019 were retrospectively analyzed. A total of 183 patients (57.4% male, 42.6% female) were included, median age 51 years old (range 19–84) 67.2% under 60 years. Extra nodal disease occurred in 47.3% of cases. Most of the cases (66.5%) were diagnosed in localized stage (I–II). Patients were categorized as International Prognostic index (IPI) low 61.3%; low-intermediate 25.2%; high intermediate 11% and high 2.5%. Revised IPI (R-IPI) categories were grouped at very good 15.4%, Good 71.0% and Poor 13.6%. Radiotherapy was associated with the R-CHOP regimen in 45.4% of cases. The objective response rate achieved was 73.8% (complete response [CR] 66.7%). After a median follow-up of 5.7 years, the 5 years overall survival (OS) rate was 71.4%. The 5 years OS rates by age ˂60 versus ≥60 years (74.1% vs. 66.2% p = 0.02), performance status 0-1 vs. 2-4 (73.5% vs. 52.9%; p = 0.042) stage I–II versus III-IV (81.2% vs. 52.9%; p ˂ 0.001), R-IPI very good versus good versus poor (89.8% vs. 74.5% vs. 49.8%; p = 0.001), CR versus No CR (84.1% vs. 38.8%; p ˂ 0.001). Multivariate analysis established that R-IPI very good category (Hazard Ratio [HR] = 2.51; 95% CI 1.14–5.51) and achieve complete response (HR = 6.89; 95% CI 3.4–13.95) were independent favorable risk factors for OS. In conclusion, this analysis of patients with DLBCL treated with R-CHOP in the real-world setting indicated that excellent outcomes are achieved, similar to those reported in the clinical trials. Keyword: aggressive B-cell non-Hodgkin lymphoma No conflicts of interests pertinent to the abstract.","journal":"Hematological Oncology","year":2023,"id":388351,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9605,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1157908,"name":"Daniel Ricardo Martínez Ávila","orcid":null,"position":1,"is_corresponding":false},{"id":1157909,"name":"Tamara González Madruga","orcid":null,"position":2,"is_corresponding":false},{"id":1157910,"name":"Brenda Benítez Caballero","orcid":null,"position":3,"is_corresponding":false},{"id":1157571,"name":"Diana Otero","orcid":"0000-0002-4735-5410","position":4,"is_corresponding":false},{"id":1157911,"name":"Julio Jiménez Galainena","orcid":null,"position":5,"is_corresponding":false},{"id":1157912,"name":"Laura Selis Pomar Durruthy","orcid":null,"position":6,"is_corresponding":false},{"id":1157913,"name":"Lázara Yinet Martínez Espinosa","orcid":null,"position":7,"is_corresponding":false},{"id":1157914,"name":"Dagmar Alfonso Estévez","orcid":null,"position":8,"is_corresponding":false},{"id":1157915,"name":"D. Sánchez Pérez","orcid":null,"position":9,"is_corresponding":false},{"id":1157916,"name":"Encamación Vásquez Olazabal","orcid":null,"position":10,"is_corresponding":false},{"id":1157907,"name":"E. A. Gracia Medina","orcid":null,"position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T01:18:13.977537Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}